Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and ve 821

pyrazines has been researched along with ve 821 in 34 studies

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's29 (85.29)24.3611
2020's5 (14.71)2.80

Authors

AuthorsStudies
Charlton, PA; Charrier, JD; Golec, JM; Griffiths, MR; Long, JM; Maccormick, S; Pollard, JR; Reaper, PM1
Anbalagan, S; Charlton, PA; Hammond, EM; McKenna, WG; Olcina, MM; Pires, IM; Pollard, JR; Reaper, PM1
Brunner, TB; Charlton, PA; Fokas, E; McKenna, WG; Muschel, RJ; Pollard, JR; Prevo, R; Reaper, PM1
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE1
Durišová, K; Lukášová, E; Novotná, E; Pejchal, J; Řezáčová, M; Sinkorová, Z; Tichý, A; Vávrová, J; Zárybnická, L1
Ďurišová, K; Fabrik, I; Link, M; Řezáčová, M; Šalovská, B; Tichý, A; Vávrová, J1
de Vries, EG; Fehrmann, RS; Franke, L; Krajewska, M; Labib, S; Schoonen, PM; van Vugt, MA1
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM1
Benes, CH; Bersani, F; Boussin, FD; Bryll, AR; Cox, KE; Flynn, RL; Ganem, NJ; Haber, DA; Jeitany, M; Pineda, JR; Suvà, ML; Wakimoto, H; Zou, L1
Chen, G; Gong, C; Liu, Y; Sun, C; Weng, D; Yang, Z1
Cortez, D; Glick, GG; Lehmann, BD; Luzwick, JW; Mohni, KN; Pendleton, CS; Pietenpol, JA; Thompson, PS1
Anderson, KC; Bianchini, G; Cottini, F; Hideshima, T; Richardson, PG; Suzuki, R; Tai, YT; Tonon, G1
Fujimori, A; Fujisawa, H; Hirakawa, H; Lee, Y; Nakajima, NI; Okayasu, R; Sunada, S; Uesaka, M; Yajima, H1
Abdel-Fatah, TM; Aleskandarany, MA; Alsubhi, N; Arora, A; Chan, SY; Curtin, NJ; Doherty, R; Ellis, IO; Green, AR; Madhusudan, S; Martin, SG; Middleton, F; Moseley, PM; Rakha, EA; Stephens, P1
Allan, JM; Curtin, NJ; Edmondson, R; Elstob, CJ; Fordham, S; Herriott, A; May, FE; McCormick, A; Middleton, FK; Patterson, MJ; Pollard, JR; Wade, MA1
Colis, LC; Herzon, SB1
Biskup, E; Gniadecki, R; Naym, DG1
Carlucci, G; Carney, B; Reiner, T; Sadique, A; Tang, J; Vansteene, A1
Bolm, C; Hartkamp, J; Hendriks, CMM; Lüscher, B; Rossetti, G; Steinkamp, AD; Wiezorek, S1
Bai, M; Che, X; Cheng, Y; Hou, K; Jing, W; Li, C; Li, H; Li, Y; Li, Z; Liu, Y; Qu, X; Song, N; Wang, K1
Ali, S; Buluwela, L; Farzan, R; Meek, DW; Saurin, AT; Smith, L1
Čecháková, L; Fabrik, I; Friedecký, D; Janečková, H; Karlíková, R; Link, M; Ondrej, M; Šalovská, B; Tichý, A1
Freire, R; Kim, D; Liu, Y; Oberly, S; Smolka, MB1
da Silva, RB; Machado, CR; Pedrosa, AL; Rodrigues, ARA1
Bao, C; Chen, H; Jung, YS; Li, X; Lian, X; Qian, Y; Zhang, X1
Bruni-Cardoso, A; Fiore, APZP; Gomes, LR; Kinker, GS; Martins, DJ; Menck, CFM; Rocha, CRR1
Arthur, G; Bebb, DG; Bolyos, A; Bose, P; Goutam, S; Jette, NR; Lees-Miller, SP; Petersen, LF; Radhamani, S; Ye, R1
Hutcherson, RJ; Kemp, MG1
Marczak, A; Poczta, A; Rogalska, A; Łukawska, M1
Andrs, M; Gorecki, L; Korabecny, J; Rezacova, M1
Bai, M; Che, X; Jing, W; Li, C; Li, Z; Liu, Y; Qu, X; Song, N; Teng, Z1
Moolmuang, B; Ruchirawat, M1
Gondhowiardjo, S; Gu, W; Kakoti, S; Kato, R; Ohno, T; Oike, T; Permata, TBM; Sato, H; Sato, I; Shibata, A; Suzuki, K; Tsushima, Y; Uchihara, Y; Yamauchi, M; Yasuhara, T; Yoshimatsu, Y1
Eck, N; Falkner, A; Georg, D; Glänzer, D; Leithner, A; Lohberger, B; Stasny, K1

Reviews

1 review(s) available for pyrazines and ve 821

ArticleYear
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
    Pharmacology & therapeutics, 2020, Volume: 210

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Drug Discovery; Drug Synergism; Humans; Isoxazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfones; Treatment Outcome

2020

Other Studies

33 other study(ies) available for pyrazines and ve 821

ArticleYear
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
    Nature chemical biology, 2011, Apr-13, Volume: 7, Issue:7

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Fibroblasts; Humans; Molecular Structure; Protein Serine-Threonine Kinases; Pyrazines; Sulfones; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2011
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.
    British journal of cancer, 2012, Jul-10, Volume: 107, Issue:2

    Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Replication; HCT116 Cells; HeLa Cells; Histones; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation Tolerance; Radiotherapy; Repressor Proteins; Signal Transduction; Sulfones; Tripartite Motif-Containing Protein 28

2012
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
    Cancer biology & therapy, 2012, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation-Sensitizing Agents; Signal Transduction; Sulfones

2012
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Cancer research, 2013, Jun-15, Volume: 73, Issue:12

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan

2013
Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60).
    Radiation and environmental biophysics, 2013, Volume: 52, Issue:4

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; DNA Repair; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Morpholines; Protein Kinase Inhibitors; Pyrazines; Pyrones; Radiation Tolerance; Sulfones

2013
Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis.
    International journal of molecular sciences, 2014, Jul-07, Volume: 15, Issue:7

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Gamma Rays; Humans; Phosphorylation; Protein Kinase Inhibitors; Proteome; Pyrazines; Radiation-Sensitizing Agents; Sulfones

2014
ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
    Oncogene, 2015, Volume: 34, Issue:26

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Drug Resistance, Neoplasm; HeLa Cells; Homologous Recombination; Humans; MCF-7 Cells; Molecular Targeted Therapy; Neoplasms; Protein Kinases; Pyrazines; Signal Transduction; Sulfones; Thiophenes; Urea

2015
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Cancer research, 2014, Dec-01, Volume: 74, Issue:23

    Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan

2014
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
    Science (New York, N.Y.), 2015, Jan-16, Volume: 347, Issue:6219

    Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; DNA Helicases; Gene Knockdown Techniques; Glioma; HeLa Cells; Homologous Recombination; Humans; Nuclear Proteins; Osteosarcoma; Promyelocytic Leukemia Protein; Pyrazines; Replication Protein A; RNA, Untranslated; Sulfones; Telomerase; Telomere; Telomere Homeostasis; Telomeric Repeat Binding Protein 2; Transcription Factors; Tumor Suppressor Proteins; X-linked Nuclear Protein

2015
[Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:11

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cisplatin; DNA Repair; Female; Humans; Ovarian Neoplasms; Pyrazines; RNA, Small Interfering; Sulfones; Transfection

2014
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Repair; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Drug Synergism; Gene Library; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Pyrazines; RNA, Small Interfering; Sulfones; Tumor Suppressor p53-Binding Protein 1

2015
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
    Cancer discovery, 2015, Volume: 5, Issue:9

    Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Chromosomal Instability; Cluster Analysis; Disease Progression; DNA Damage; DNA Replication; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxidative Stress; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazines; Reactive Oxygen Species; Sulfones

2015
VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation.
    Radiation oncology (London, England), 2015, Aug-19, Volume: 10

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Heavy Ion Radiotherapy; Humans; Linear Energy Transfer; Pyrazines; Radiation-Sensitizing Agents; Sulfones

2015
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
    Molecular oncology, 2016, Volume: 10, Issue:2

    Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Checkpoint Kinase 1; Cohort Studies; DNA Repair; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Humans; Indoles; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Phosphorylation; Protein Kinases; Pyrazines; Pyridones; Radiation Tolerance; RNA Interference; RNA, Small Interfering; Serine; Sulfones; Up-Regulation

2016
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Oncotarget, 2015, Oct-20, Volume: 6, Issue:32

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; CHO Cells; Computational Biology; Cricetinae; Cricetulus; Databases, Genetic; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Molecular Targeted Therapy; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Sulfones; Time Factors; Transfection

2015
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
    Bioorganic & medicinal chemistry letters, 2016, 07-01, Volume: 26, Issue:13

    Topics: Apoptosis; Cell Survival; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Fluorenes; Humans; K562 Cells; Molecular Structure; Pyrazines; Stereoisomerism; Structure-Activity Relationship; Sulfones

2016
Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Journal of dermatological science, 2016, Volume: 84, Issue:3

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Flow Cytometry; Histones; Humans; Isoxazoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Photochemotherapy; Photosensitizing Agents; Pyrazines; Quinolines; Quinuclidines; RNA, Small Interfering; Sulfones; Tumor Cells, Cultured; Ultraviolet Rays

2016
Evaluation of [
    Nuclear medicine and biology, 2017, Volume: 48

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorine Radioisotopes; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazines; Radioactive Tracers; Radiochemistry; Sulfones; Tissue Distribution

2017
Sulfoximines as ATR inhibitors: Analogs of VE-821.
    Bioorganic & medicinal chemistry letters, 2017, 06-15, Volume: 27, Issue:12

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Humans; Imines; Molecular Structure; Protein Kinase Inhibitors; Pyrazines; Structure-Activity Relationship; Sulfones

2017
ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:5

    Topics: Ataxia Telangiectasia Mutated Proteins; Cadherins; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Checkpoint Kinase 1; DNA Damage; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Humans; Nuclear Proteins; Phosphorylation; Pyrazines; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Sulfones; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1

2018
The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.
    Scientific reports, 2017, 11-23, Volume: 7, Issue:1

    Topics: Benzimidazoles; Cell Cycle Proteins; Cell Survival; Centrosome; Fluorescent Antibody Technique; Gene Silencing; HCT116 Cells; Humans; Mitosis; Morpholines; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazines; Pyrones; Sulfones; Thiophenes; Tumor Suppressor Protein p53

2017
Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells.
    PloS one, 2018, Volume: 13, Issue:7

    Topics: Amino Acid Motifs; Ataxia Telangiectasia Mutated Proteins; Binding Sites; Biomarkers; Cell Cycle Checkpoints; Cell Line, Tumor; Computational Biology; Gamma Rays; Gene Ontology; Humans; Metabolome; Metabolomics; Phosphoproteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Sulfones; TOR Serine-Threonine Kinases

2018
ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells.
    Nucleic acids research, 2018, 09-19, Volume: 46, Issue:16

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Humans; Morpholines; Neoplasm Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Protein Stability; Proteome; Pyrazines; Pyrones; Recombinational DNA Repair; Signal Transduction; Sulfones; Transcription, Genetic

2018
Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to oxidative damage.
    PloS one, 2018, Volume: 13, Issue:9

    Topics: Ataxia Telangiectasia Mutated Proteins; Humans; Leishmania major; Life Cycle Stages; Morpholines; Oxidative Stress; Pyrazines; Pyrones; Signal Transduction; Sulfones

2018
Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Journal of virology, 2019, 05-01, Volume: 93, Issue:9

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Avian Proteins; Cell Line; Checkpoint Kinase 1; Chickens; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Mardivirus; Marek Disease; Pyrazines; STAT3 Transcription Factor; Sulfones; Tumor Suppressor Protein p53; Virus Replication

2019
ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Cell death & disease, 2019, 06-12, Volume: 10, Issue:6

    Topics: A549 Cells; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Autophagy; Breast Neoplasms; Cell Culture Techniques; Cellular Microenvironment; Cellular Senescence; Checkpoint Kinase 1; Cisplatin; DNA Damage; DNA Replication; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Female; Histones; Humans; MCF-7 Cells; Pyrazines; S Phase Cell Cycle Checkpoints; Sulfones; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2019
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    British journal of cancer, 2019, Volume: 121, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Gene Deletion; Histones; Humans; Lung Neoplasms; Mutation; Nitroso Compounds; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrimidines; RNA, Messenger; Sulfones; Tumor Suppressor Protein p53

2019
ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
    Mutation research, 2019, Volume: 816-818

    Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Adducts; DNA Damage; DNA Repair; Humans; Indoles; Morpholines; Mutagenesis; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Signal Transduction; Sulfonamides; Sulfones; Sulfoxides

2019
Antileukemic activity of novel adenosine derivatives.
    Scientific reports, 2019, Oct-01, Volume: 9, Issue:1

    Topics: Adenosine; Amidines; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caspases; Cell Line; Cell Line, Tumor; Cladribine; DNA Fragmentation; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Pyrazines; S Phase; Sulfones; THP-1 Cells

2019
PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
    Medical oncology (Northwood, London, England), 2020, Apr-10, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Pyrazines; Sulfones; Tumor Suppressor Protein p53; Up-Regulation

2020
The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
    The Journal of pharmacy and pharmacology, 2021, Mar-01, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; DNA Damage; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazines; Pyrones; Sulfones; Tumor Suppressor Protein p53

2021
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
    Journal of radiation research, 2021, Sep-13, Volume: 62, Issue:5

    Topics: Ataxia Telangiectasia Mutated Proteins; B7-H1 Antigen; Bone Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Heavy Ion Radiotherapy; Humans; Imaging, Three-Dimensional; Interferon Regulatory Factor-1; Linear Energy Transfer; Morpholines; Neoplasm Proteins; Osteosarcoma; Phosphorylation; Protein Processing, Post-Translational; Pyrazines; Pyrones; RNA, Messenger; RNA, Neoplasm; STAT1 Transcription Factor; Sulfones; Up-Regulation; X-Rays

2021
The ATR Inhibitor VE-821 Enhances the Radiosensitivity and Suppresses DNA Repair Mechanisms of Human Chondrosarcoma Cells.
    International journal of molecular sciences, 2023, Jan-24, Volume: 24, Issue:3

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; DNA Damage; DNA Repair; Humans; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; Sulfones

2023